Background: Patients with COVID-19 are at increased risk from thromboembolic phenomena. Patient-specific factors such as comorbidities and immobility have been linked to thrombosis. Disease-specific factors such as virus-induced endothelial changes and cytokine storm may also be triggers. Furthermore, patients with elevated …
In this 20-minute presentation from Rebellion in EM 2021, Dr. J Scott Wieters, MD discusses the evidence for and against the use of tranexamic acid for hemorrhage alleviation in gastrointestinal bleeding by doing a critical appraisal of the HALT-IT trial.
Background: Patients with COVID-19 are at a high risk for the development of venous thromboembolic disease [Link is HERE]. Alveolar capillary microthrombi appear to be 9x more prevalent in patients with COVID-19 compared to H1N1. As a result, enhanced-dose anticoagulation …
Take Home Points Infuse factor first, investigate later Treat when bleeding is suspected, not confirmed. Have a low threshold! It is better to over treat than undertreat. Give full dose when in doubt Factor 8 = 50U/kg Factor 9 = …
Take Home Points SVT >5cm or <3 cm from the SFJ should be treated with anti-coagulation. The rate of concurrent DVT and PE in patients with SVT is 25% and 5%, respectively.
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
